Coagulation activation in patients undergoing directional coronary atherectomy

Thrombosis Research

Volumn 86, Issue 6, 1997, Pages 433-441

  Lins, Markus ^a   Zurborn, Karl Heinz ^a   Dau, Oliver ^a   Nagel, Eike ^a   Muurling, Stella ^a   Herrmann, Gunhild ^a   Simon, Rüdiger ^a  

^a NONE

Author keywords

Clotting activation; Directional coronary atherectomy; Fibrinolysis; Restenosis

Indexed keywords

ANTITHROMBIN III; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBIN;

ADULT; AGED; ARTICLE; ATHERECTOMY; BLOOD CLOTTING; CINEANGIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; FEMALE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; MALE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANTITHROMBIN III; ATHERECTOMY, CORONARY; BLOOD COAGULATION; CASE-CONTROL STUDIES; CONSTRICTION, PATHOLOGIC; CORONARY DISEASE; CORONARY VESSELS; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; PROTHROMBIN; RECURRENCE; RISK FACTORS; TIME FACTORS;

EID: 0030740285     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00092-3     Document Type: Article

References (23)

1. HIRSCHFELD J.W. Jr., SCHWARTZ J.S., JUGO R.et al. Restenosis after coronary angiography: a multivariate statistical model to relate lesion and procedure variables of restenosis. J Am Coll Cardiol. 18:1991;642-656.
2. BEATT K.J., SERRUYS P.W., HUGENHOLTZ P.G. Restenosis after coronary angioplasty: new standards for clinical studies. J Am Coll Cardiol. 15:1990;491-498.
3. POPMA J.J., CALIFF R.M., TOPOL E.J. Clinical trials of restenosis after coronary angioplasty. Circulation. 84:1991;1426-1436.
4. SERRUYS P.W., FOLEY D.P., DE FREYTER P.J. Restenosis after coronary angioplasty: a proposal of new comparative approaches based on quantitative angiography. Br Heart J. 68:1992;417-428.
5. HOEFLING, B., GONSCHIOR, P., SIMPSON, L., BAURIEDEL, G., NEHRLICH, A.: Efficacy of directional coronary atherectomy in case unsuitable for percoutaneus transluminal coronary angioplasty (PTCA) and after unsuccessful PTCA. Am Heart J, 124: 341-8.
6. TOPOL E.J., LEYA F., PINKERTON C.A., WHITLOW P.L.et al. for the CAVEAT STUDY GROUP: A comparison of directional atherectomy with coronary angioplasty in patiens with coronary artery disease. N Engl J Med. 329:1993;221-227.
7. HINOHARA T., ROBERTSON G.C., SELMON M.R., VETTER J.W., ROWE M.H., BRADEN L.J., MC AULEY B.J., SHEEHAN D.J., SIMPSON J.B. Restenosis after directional coronary atherectomy. J Am Coll Cardiol. 20:1992;623-632.
8. GRAM J., JESPERSEN J.A. A simple estimation of tissue plasminogen activator (t-PA) inhibition in human plasma. Fibrinolysis. 1:1987;33-37.
9. ADELMAN A.G., COHEN E.A., KIMBALL B.P., BONAN R.et al. A comparison of directional atherectomy with coronary angioplasty for lesions of the left anterior descending coronary artery. N Engl J Med. 329:1993;228-233.
10. GRAM J., JESPERSEN J., KLUFT C., RIJKEN D.C. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Sand. 221:1987;149-153.
11. HAMSTEN, A., DE FAIRE, U., WALLDIUS, G., DAHLEN, G., SZAMOSI, A., LANDOU, C., BLOMBÄCK, M., WIMAN, B.: Plasminogen activator inhibitor in plasma: risk factor for reccurent myocardial infarction. Lancet, ii: 3-9, 1987.
12. PRINS M.H., HIRSH J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J. 122:1991;545-551.
13. MUNKVAD S., JESPERSEN J., GRAM J., KLUFT C. Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischemic heart disease. Possible role of the endothelium. J Intern Med. 228:1990;361-366.
14. BAUER K.A., ROSENBERG R.D. Thrombin generation in acute promyelocytic leukemia. Blood. 64:1984;791-796.
15. PELZER H., FUHGE P., BLEYL H., HEIMBURGER N. Enzyme immunoassay for determination of human thrombin-antithrombin III complex. Thromb Haemost. 24:1985;101-106.
16. PELZER H., SCHWARZ A., STÖBER W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 65:1991;153-159.
17. CHMIELEWSKA J., RÅNBY M., WIMAN B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res. 31:1983;427-436.
18. CHESEBRO J.H., ZOLDHELYI P., BADIMON L., FUSTER V. Role of thrombin in arterial thrombosis: implications for therapy. Thromb Haemost. 66:1991;1-5.
19. ROSS R. The pathogenesis of atherosclerosis - an update. N Engl J Med. 314:1986;488-500.
20. CLOWES A.W. Prevention and management of reccurent disease after arterial reconstruction: new prospects for pharmacological control. Thromb Haemost. 66:1991;62-66.
21. ASTRUP T. The biological significance of fibrinolysis. Lancet. 2:1956;565-568.
22. HERAS M., CHESEBRO J.H., PENNY W.J., BAILEY K.R., BADIMON L., FUSTER V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation. 79:1989;657-665.
23. ZURBORN, K.H., MEYER, S., HERRMANN, G., SIMON, R., BRUHN, H.D.: Reduced fibrinolytic capacity and prolonged disturbance of hemostatic balance in patients with restenosis following percutaneous transluminal coronary angioplasty (PTCA). Ann Hematol, 66: Suppl I: A59.